Home » Market News » DirectorsTalk Highlights » GREAT Festival of Innovation
Oncimmune Holdings PLC

GREAT Festival of Innovation

Maarten Brusse, Chief Commercial Officer Asia, will be presenting at the GREAT Festival of Innovation taking place from 21-24 March 2018 in Hong Kong.  During his presentation, scheduled to take place from 10.50 – 11.15am on Thursday 22 March. Maarten will provide an update on Oncimmune’s EarlyCDT® platform technology.

Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. The Company now has a “kit” version of EarlyCDT®-Lung currently being commercialised and there are several distribution agreements in place for Europe and the Asia Pacific region, including in China. EarlyCDT® tests for liver and ovarian cancer are in development.

The GREAT Festival takes place at a historic moment for the UK, Hong Kong and Asian economies. It will enable the sharing of innovations that will drive the future of free trade and build life-long partnerships. Over four days, the Festival will offer a series of thought-provoking and lively keynotes, masterclasses, showcases, installations and performances involving industry leaders, entrepreneurs, artists, educationalists, futurologists to an audience from the UK, Hong Kong, China, Japan, South Korea and wider region.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.